Novo Holdings A/S
13F filer · CIK 0001388325Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.72BU.S. long equity reported on 13F
Positions256 new · 3 closed
Net flow last quarter+$205MBuys minus sells
Top 10 positions weight73.5%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202625 positions | |||||
| $217M | 12.62% | 4.96% | Not reported | Q1 2021 | |
| $189M | 10.97% | 0.02% | Not reported | Q1 2022 | |
| $154M | 8.92% | 8.95% | New | Q2 2026 | |
| $150M | 8.68% | Not reported | Not reported | Q3 2023 | |
| $132M | 7.67% | 8.11% | Not reported | Q4 2025 | |
| $132M | 7.65% | 1.74% | -15.1% | Q3 2019 | |
| $128M | 7.42% | 8.76% | New | Q2 2026 | |
| $61.6M | 3.58% | 0.05% | Not reported | Q1 2022 | |
| $52.1M | 3.03% | 3.10% | -22.8% | Q1 2024 | |
| $50.8M | 2.95% | 1.37% | -21.9% | Q2 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $49.4M | 2.87% | 1.25% | -14.8% | Q3 2018 |
| $48.4M | 2.81% | 2.15% | -20.0% | Q1 2021 | |
| $47.3M | 2.75% | 0.75% | New | Q2 2026 | |
| $46.5M | 2.70% | 0.55% | -7.0% | Q2 2020 | |
| $43.2M | 2.51% | 5.88% | -11.0% | Q1 2023 | |
| $39.2M | 2.28% | 1.89% | +6.8% | Q1 2024 | |
| $38.1M | 2.21% | 1.31% | -14.6% | Q2 2024 | |
| $31M | 1.80% | Not reported | New | Q2 2026 | |
| $29.3M | 1.70% | 0.50% | Not reported | Q4 2014 | |
| $24.7M | 1.43% | 0.01% | Not reported | Q1 2021 | |
| $21.3M | 1.24% | 0.58% | New | Q2 2026 | |
| $17.1M | 1.00% | 2.81% | +2.9% | Q3 2025 | |
| $12.9M | 0.75% | 0.06% | Not reported | Q2 2020 | |
| $7.17M | 0.42% | Not reported | Not reported | Q4 2021 | |
| $1.08M | 0.06% | 1.21% | Not reported | Q1 2023 | |
| Q1 2026Reported May 15, 202622 positions | |||||
| $169M | 13.65% | 4.98% | Not reported | Q1 2021 | |
| $141M | 11.46% | Not reported | Not reported | Q3 2023 | |
| $125M | 10.16% | 0.02% | -16.7% | Q1 2022 | |
| $122M | 9.92% | 2.17% | +4.8% | Q3 2019 | |
| $74.9M | 6.07% | 8.15% | Not reported | Q4 2025 | |
| $73.4M | 5.95% | 0.04% | +19.1% | Q1 2022 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $56.3M | 4.56% | 1.47% | -4.6% | Q3 2018 |
| $50.2M | 4.07% | 2.10% | -13.5% | Q2 2025 | |
| $50M | 4.05% | 0.60% | -6.1% | Q2 2020 | |
| $49.4M | 4.01% | 2.68% | Not reported | Q1 2021 | |
| $44.8M | 3.63% | 4.29% | Not reported | Q1 2024 | |
| $39.1M | 3.17% | 1.95% | -16.0% | Q1 2024 | |
| $38.1M | 3.08% | 1.80% | Not reported | Q2 2024 | |
| ATAPGEApogee Therapeutics, Inc. | $37.9M | 3.07% | 0.60% | -21.1% | Q2 2025 |
| $37.3M | 3.02% | 0.34% | Not reported | Q2 2022 | |
| $34M | 2.75% | 6.98% | Not reported | Q1 2023 | |
| $32.3M | 2.62% | 0.01% | Not reported | Q1 2021 | |
| $28.2M | 2.29% | 0.50% | Not reported | Q4 2014 | |
| $19.6M | 1.59% | 2.73% | +11.5% | Q3 2025 | |
| $6.61M | 0.54% | 0.61% | -54.1% | Q2 2025 | |
| $2.53M | 0.21% | 1.57% | Not reported | Q1 2023 | |
| $1.8M | 0.15% | Not reported | Not reported | Q4 2021 | |
| Q4 2025Reported Feb 17, 202624 positions | |||||
| $160M | 12.46% | Not reported | Not reported | Q3 2023 | |
| $133M | 10.31% | 5.04% | Not reported | Q1 2021 | |
| $122M | 9.47% | 0.03% | -21.9% | Q1 2022 | |
| $99.8M | 7.75% | 2.44% | Not reported | Q3 2019 | |
| $87.5M | 6.79% | 0.04% | Not reported | Q1 2022 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $75.6M | 5.87% | 1.70% | Not reported | Q3 2018 |
| $74.1M | 5.75% | 2.34% | Not reported | Q1 2024 | |
| $64.8M | 5.03% | 8.37% | New | Q4 2025 | |
| $52.6M | 4.09% | 2.66% | -27.5% | Q3 2024 | |
| $48.6M | 3.77% | 2.68% | Not reported | Q1 2021 | |
| ATAPGEApogee Therapeutics, Inc. | $43M | 3.34% | 0.83% | +14.0% | Q2 2025 |
| $42.3M | 3.28% | 0.70% | Not reported | Q2 2020 | |
| $39.2M | 3.05% | 0.34% | Not reported | Q2 2022 | |
| $39.1M | 3.03% | 4.57% | Not reported | Q1 2024 | |
| $37.7M | 2.93% | 0.00% | Not reported | Q1 2021 | |
| $34.8M | 2.70% | 0.09% | Not reported | Q2 2020 | |
| $32.6M | 2.53% | 1.80% | Not reported | Q2 2024 | |
| $27.4M | 2.13% | 6.34% | +82.5% | Q1 2023 | |
| $24.6M | 1.91% | 2.45% | Not reported | Q3 2025 | |
| $22.8M | 1.77% | 2.49% | +3.8% | Q2 2025 | |
| $20.3M | 1.58% | 1.33% | -1.7% | Q2 2025 | |
| $2.18M | 0.17% | 6.82% | Not reported | Q1 2023 | |
| $2.1M | 0.16% | Not reported | Not reported | Q4 2021 | |
| IBIOBTQIO Biotech, Inc. | $1.53M | 0.12% | 3.49% | Not reported | Q4 2021 |
| Q3 2025Reported Nov 14, 202526 positions | |||||
| $160M | 10.30% | Not reported | Not reported | Q3 2023 | |
| $141M | 9.10% | 0.04% | -12.1% | Q1 2022 | |
| $92.7M | 5.97% | 2.46% | -15.7% | Q3 2019 | |
| $86.8M | 5.59% | 5.06% | Not reported | Q1 2021 | |
| $78.3M | 5.04% | 0.03% | Not reported | Q1 2022 | |
| MMRUSMerus N.V. | $70.6M | 4.55% | 0.99% | Not reported | Q2 2016 |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $67.7M | 4.36% | 1.72% | +4.8% | Q3 2018 |
| $51.4M | 3.31% | 2.89% | Not reported | Q1 2024 | |
| $46M | 2.96% | 0.00% | -30.9% | Q1 2021 | |
| $44.4M | 2.86% | 4.74% | -11.1% | Q3 2024 | |
| $43.7M | 2.81% | 3.22% | +1.5% | Q1 2021 | |
| $38.7M | 2.49% | 1.61% | -18.0% | Q4 2024 | |
| $35.8M | 2.31% | 4.75% | +3.7% | Q1 2024 | |
| $35.7M | 2.30% | 0.34% | Not reported | Q2 2022 | |
| $33M | 2.13% | 0.70% | Not reported | Q2 2020 | |
| $31M | 2.00% | 1.81% | Not reported | Q2 2024 | |
| $29.2M | 1.88% | 2.41% | +31.5% | Q2 2025 | |
| $28.8M | 1.86% | 0.09% | -70.6% | Q2 2020 | |
| $28.6M | 1.84% | 1.44% | -1.3% | Q2 2025 | |
| $22.7M | 1.46% | 2.48% | New | Q3 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $19.9M | 1.28% | 0.84% | +11.3% | Q2 2025 |
| $17.4M | 1.12% | 4.28% | Not reported | Q1 2023 | |
| $3.88M | 0.25% | 6.82% | 0.0% | Q1 2023 | |
| $2.33M | 0.15% | Not reported | Not reported | Q4 2021 | |
| IBIOBTQIO Biotech, Inc. | $912K | 0.06% | 3.61% | -25.1% | Q4 2021 |
| $322K | 0.02% | 6.52% | -13.4% | Q3 2024 | |
Premium opens every quarter this fund has filed